诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

农历年初二休市 02-16 12:08:06

12.430

-0.230

-1.82%

最高12.700	最低12.310	成交量39.60万
今开12.700	昨收12.660	日振幅3.08%
总市值219.02亿	流通市值185.70亿	总股本17.62亿
成交额493.47万	换手率0.03%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":12.43,"timestamp":1771214886010,"preClose":12.66,"halted":0,"volume":396000,"delay":0,"changeRate":-0.018167456556082182,"floatShares":1494000000,"shares":1762000000,"eps":-0.27,"marketStatus":"农历年初二休市","change":-0.23,"latestTime":"02-16 12:08:06","open":12.7,"high":12.7,"low":12.31,"amount":4934650,"amplitude":0.030806,"askPrice":12.43,"askSize":1000,"bidPrice":12.38,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.143,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771551000000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":12.66,"openAndCloseTimeList":[[1771205400000,1771214400000]],"volumeRatio":0.1110587148761376,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":24.2,"timestamp":1770966000000,"preClose":24.38,"halted":0,"volume":6751600,"delay":0,"premium":"-54.73"}},"requestUrl":"/m/hq/s/09969/tweets","defaultTab":"tweets","newsList":[{"id":"2611607771","title":"每日卖空追踪 | 诺诚健华 02月13日卖空量成交12.9万股，卖空比例为4.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611607771","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611607771?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:30","pubTimestamp":1770971444,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间02月13日，涨0.48%，卖空量成交12.9万股，较上一交易日减少85.95%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213163641a49ffc27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213163641a49ffc27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09969"],"gpt_icon":0},{"id":"2610187799","title":"诺诚健华携手清华大学获批北京重点实验室","url":"https://stock-news.laohu8.com/highlight/detail?id=2610187799","media":"中国网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610187799?lang=zh_cn&edition=full","pubTime":"2026-02-12 13:33","pubTimestamp":1770874412,"startTime":"0","endTime":"0","summary":"中国网财经2月12日讯近日，北京市科学技术委员会、中关村科技园区管理委员会公布了2025年北京市重点实验室认定名单。由清华大学作为依托单位，诺诚健华作为共建单位联合申报的“口服药物智能设计与递送北京市重点实验室”成功获批。“口服药物智能设计与递送北京市重点实验室”是合作双方长期深耕、协同创新的重要里程碑，标志着合作从项目层面迈向体系化、平台化的新阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602123649065380.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123649065380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","688428","BK1161","BK0239"],"gpt_icon":0},{"id":"2610695841","title":"每日卖空追踪 | 诺诚健华 02月11日卖空量成交26.5万股，卖空比例为2.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610695841","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610695841?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:30","pubTimestamp":1770798646,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间02月11日，跌3.56%，卖空量成交26.5万股，较上一交易日减少76.63%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163633a6ee20ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163633a6ee20ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2610451958","title":"诺诚健华02月11日主力净流出220.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2610451958","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610451958?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:16","pubTimestamp":1770797763,"startTime":"0","endTime":"0","summary":"02月11日, 诺诚健华股价跌3.56%，报收12.73元，成交金额1.3亿元，换手率0.68%，振幅4.77%，量比0.86。诺诚健华今日主力资金净流出220.7万元，上一交易日主力净流入578.6万元。该股近5个交易日上涨11.86%，主力资金累计净流入2428.6万元；近20日主力资金累计净流出2723.9万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211162243a49723c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211162243a49723c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2610584189","title":"全球首个！诺诚健华 BTK 启动新自免 III 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2610584189","media":"求实药社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610584189?lang=zh_cn&edition=full","pubTime":"2026-02-11 11:56","pubTimestamp":1770782174,"startTime":"0","endTime":"0","summary":"来源：丁香园 Insight 数据库2025 年 12 月，诺诚健华宣布奥布替尼在治疗系统性红斑狼疮的 IIb 期临床研究中达到主要终点。诺诚健华新闻稿指出，奥布替尼是全球首个在 SLE II 期临床试验中展示显著疗效的 BTK 抑制剂。同时，奥布替尼显示出良好的耐受性和安全性，安全性特征与 BTK 抑制剂的作用机制和 SLE 的疾病生物学相一致。与此同时，诺诚健华预计 2025 年归母净利润首次扭亏为盈，达到 6.3 亿元左右。据悉，奥布替尼 2025 年前三季度收入同比上涨 45.8%，达到 10.1 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211122937a4965703&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211122937a4965703&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","BK1574"],"gpt_icon":0},{"id":"2610958464","title":"系统性红斑狼疮治疗迎利好，诺诚健华、阿斯利康等多药企创新药获新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2610958464","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610958464?lang=zh_cn&edition=full","pubTime":"2026-02-11 11:23","pubTimestamp":1770780180,"startTime":"0","endTime":"0","summary":"全球超340万系统性红斑狼疮（SLE）患者，中国约100万，药物需求迫切。国内药企持续发力，2月10日，杭州尚健生物自主研发的SG301 SC注射液获受理，为国内首个获批临床的皮下注射抗CD38人源化单克隆抗体，早期临床数据显示其安全性和有效性良好；2月9日，诺诚健华自主研发的VAV1分子胶降解剂ICP-538获批开展临床研究，其核心产品奥布替尼用于治疗SLE的三期临床试验也已获批开展。国际药企也在加速布局，阿斯利康旗下生物制剂Saphnelo在亚洲人群中的III期临床试验取得积极成果，在降低疾病活动度和减少口服糖皮质激素用量方面均有改善。此外，已有多款创新药在中国获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211113516a6ed165b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211113516a6ed165b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","06978","BK1161"],"gpt_icon":0},{"id":"2610268695","title":"恒生医疗保健指数升2.17%  医药板块普遍拉升 机构持续看好中国创新药出海的产业趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=2610268695","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610268695?lang=zh_cn&edition=full","pubTime":"2026-02-10 09:59","pubTimestamp":1770688793,"startTime":"0","endTime":"0","summary":"2月8日，信达生物宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。2026年，继续看好中国创新药出海的产业趋势，继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会，期待JPM大会、ASCO等带来数据更新和BD催化。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8f73ea90e21e93e4b02cf2f8986a9c30","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974845","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","LU0196878994.USD","LU2476274720.SGD","02359","02269","LU0502904849.HKD","LU2039709279.SGD","LU1720050803.USD","BK1587","LU0634319403.HKD","IE00B5MMRT66.SGD","LU1961090484.USD","LU0359202008.SGD","06978","LU0140636845.USD","01801","LU0417516738.SGD","HK0000306701.USD","02696","09969","LU0516423174.USD","BK1161","LU0516422366.SGD","159992","LU1688375341.USD","LU2045819591.USD","09688","02268","LU2476274308.USD","LU0043850808.USD","LU0572944931.SGD","03347","159506","06990","LU0823426308.USD","159938","09995","LU1046422090.SGD","02162","01877","LU0051755006.USD","LU0856984785.SGD","LU2242644610.SGD","LU2488822045.USD","LU1969619763.USD","09926","LU0417516902.SGD","LU0348825331.USD","LU0181495838.USD","09939"],"gpt_icon":1},{"id":"2609258485","title":"每周股票复盘：诺诚健华（688428）1月31日股本无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2609258485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609258485?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:39","pubTimestamp":1770485948,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，诺诚健华报收于24.02元，较上周的21.4元上涨12.24%。本周，诺诚健华2月6日盘中最高价报24.58元。诺诚健华当前最新总市值423.87亿元，在化学制药板块市值排名12/150，在两市A股市值排名477/5186。本周关注点公司公告汇总：诺诚健华截至2026年1月31日已发行股份为1,496,284,235股，库存股2,486,000股，无增减变动。公司公告汇总诺诚健华医药有限公司截至2026年1月31日，法定注册资本为250亿股普通股，每股面值0.000002美元，总法定股本5万美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","09969","688428"],"gpt_icon":0},{"id":"2609563163","title":"2月6日诺诚健华涨10.13%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609563163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609563163?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:32","pubTimestamp":1770366770,"startTime":"0","endTime":"0","summary":"证券之星消息，2月6日诺诚健华涨10.13%，收盘报24.02元，换手率8.82%，成交量23.67万手，成交额5.56亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元，最新净值2.9402，较上一交易日上涨0.56%，近一年上涨35.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600027021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1574","BK1161","688428","BK0239"],"gpt_icon":0},{"id":"2609546312","title":"每日卖空追踪 | 诺诚健华 02月06日卖空量成交192.7万股，卖空比例为7.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609546312","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609546312?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:30","pubTimestamp":1770366644,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间02月06日，涨8.45%，卖空量成交192.7万股，较上一交易日增加261.54%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163812a6dac71a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163812a6dac71a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"1197197181","title":"港股生物医药板块走高，诺诚健华、再鼎医药涨超4%，药明康德、药明生物等个股跟涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1197197181","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197197181?lang=zh_cn&edition=full","pubTime":"2026-02-05 15:24","pubTimestamp":1770276262,"startTime":"0","endTime":"0","summary":"2月5日，港股$生物(000504)$医药板块走高，$诺诚健华(09969)$、$再鼎医药(09688)$涨超4%，$药明康德(02359)$、$药明$生物(000504)$(02269)$等个股跟涨。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4d7f9f320a213719065b5b2c9bc96e8b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1046422090.SGD","LU1934453819.USD","LU0348825331.USD","LU2039709279.SGD","LU0417516738.SGD","02359","SG9999002562.SGD","LU0516422366.SGD","LU2125910500.SGD","LU0327786744.USD","BK1610","LU1808992512.USD","LU0307460666.USD","LU1880383366.USD","02269","BK1574","LU0823426308.USD","LU3063872942.SGD","LU1242518857.USD","BK1161","BK1588","LU2495084118.USD","09688","399441","LU1997245177.USD","BK4526","BK4139","LU0516423174.USD","LU0979878070.USD","LU1242518931.SGD","BK1576","LU0819121731.USD","SG9999002463.SGD","LU0359201612.USD","BK0239","LU0039217434.USD","LU1997245094.SGD","IE00B0JY6N72.USD","BK4531","LU0320764599.SGD","LU1997244956.HKD","LU0052750758.USD","LU0051755006.USD","LU0456842615.SGD","LU0348735423.USD","LU0456827905.SGD","BK1583","LU0359202008.SGD","LU0823426480.USD","BK1589","LU2242644610.SGD","LU0856984785.SGD","LU0456846285.SGD","LU0588546209.SGD","LU0140636845.USD","LU0708995583.HKD","LU0043850808.USD","BK4585","LU0572944931.SGD","LU0516422440.USD","BK1141","09969","LU0417516902.SGD","LU0516422952.EUR","LU2045819591.USD","LU0181495838.USD","LU1794554557.SGD","LU0326950275.SGD","BK0216","LU1720050803.USD","LU2328871848.SGD","LU2488822045.USD","LU1979443071.USD","LU1688375341.USD","BK4548","LU1969619763.USD","LU0516423091.SGD","BK1521","BK4588"],"gpt_icon":0},{"id":"2609346495","title":"港股异动 | 诺诚健华(09969)早盘涨超4% 公司首次实现扭亏为盈 核心产品奥布替尼贡献显著增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2609346495","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609346495?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:50","pubTimestamp":1770259821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华早盘涨超4%，截至发稿，涨3.95%，报11.83港元，成交额3869.91万港元。消息面上，诺诚健华此前发布业绩预告，预计2025年实现收入23.7亿元，同比增长约134%；预计2025年归母净利润首次扭亏为盈，达6.3亿元左右。核心产品奥布替尼贡献显著增量，2025年5月坦昔妥单抗获批上市后进一步丰富药品收入来源。值得注意的是，诺诚健华宣布，公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组，总共入组383例患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","BK1574","688428","09969","BK4588","VT","VXUS","BK4585"],"gpt_icon":0},{"id":"2608398843","title":"诺诚健华（688428）披露证券变动月报表，2月4日股价上涨1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608398843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608398843?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:26","pubTimestamp":1770215179,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，诺诚健华报收于21.51元，较前一交易日上涨1.8%，最新总市值为379.57亿元。该股当日开盘21.06元，最高21.72元，最低20.9元，成交额达1.91亿元，换手率为3.34%。近日，诺诚健华医药有限公司发布证券变动月报表。公司确认已符合香港联交所规定的公众持股量要求。此外，公告提及2023年及2024年人民币股份激励计划的相关安排，涉及部分限制性股票失效情况，但本月未因相关协议导致股份变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK1574","BK1161","09969","161027","BK0239"],"gpt_icon":0},{"id":"2608036200","title":"诺诚健华：公司预计2025年度首次实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2608036200","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608036200?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:38","pubTimestamp":1770212317,"startTime":"0","endTime":"0","summary":"证券日报网讯2月4日，诺诚健华在互动平台回答投资者提问时表示，公司在管线推进、商业化拓展等方面均按照计划及目标顺利推进，经营一切正常，不存在经营困境。根据公司业绩预告，公司预计2025年度首次实现扭亏为盈，预计2025年实现营业总收入人民币23.65亿元左右，与上年同期相比增长134%左右，归属于母公司所有者的净利润为6.33亿元左右。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043641731339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","688428","09969","BK0239"],"gpt_icon":0},{"id":"2609746343","title":"每日卖空追踪 | 诺诚健华 02月04日卖空量成交14.5万股，卖空比例为2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609746343","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609746343?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:30","pubTimestamp":1770193843,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间02月04日，涨1.07%，卖空量成交14.5万股，较上一交易日减少83.16%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163859a47b11a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163859a47b11a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","BK1574"],"gpt_icon":0},{"id":"2608875572","title":"283只医药股披露2025年业绩预告：药明康德最能赚、创新药企业走向盈利分界线，疫苗企业业绩承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2608875572","media":"每经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608875572?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:52","pubTimestamp":1770115974,"startTime":"0","endTime":"0","summary":"Wind数据显示，截至1月31日，共有283只医药股披露了2025年业绩预告。赛诺医疗预计，公司2025年归母净利润为4300万元至5000万元，同比增长2767%至3233%。此外，披露2025年度业绩预告的医药股中，药明康德预计净利润为191.51亿元，创公司上市以来的归母净利润新高。多家创新药企业预计扭亏、减亏披露业绩预告的创新药企中，不少企业出现净利扭亏、减亏的情形。此外，盟科药业、君实生物等创新药企虽未实现盈利，但已大幅减亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203185354a6ce4350&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203185354a6ce4350&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1515","LU2125910500.SGD","BK1574","BK1583","09969","LU0708995583.HKD","BK1141","01877","LU2045819591.USD","BK1161","LU0052750758.USD","LU1046422090.SGD","LU0320764599.SGD","09995","02359","06978","LU2242644610.SGD","09939"],"gpt_icon":0},{"id":"2608850327","title":"每日卖空追踪 | 诺诚健华 02月02日卖空量成交92.3万股，卖空比例为8.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608850327","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608850327?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:30","pubTimestamp":1770021042,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间02月02日，跌1.79%，卖空量成交92.3万股，较上一交易日减少84.83%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163929a4729156&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163929a4729156&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2608880406","title":"诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608880406","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608880406?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:50","pubTimestamp":1769993437,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月2日，诺诚健华官微宣布，公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组，总共入组383例患者。这一里程碑标志着ICP-488治疗银屑病取得重大临床进展，有望为银屑病患者带来新的口服治疗选择。这项临床试验为多中心、随机、双盲、安慰剂对照，旨在评价ICP-488单药治疗中重度斑块状银屑病成人患者的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638037294.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638037294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","III","09969","688428","BK4134","BK1161","BK0239"],"gpt_icon":0},{"id":"2608072758","title":"每周股票复盘：诺诚健华（688428）预计2025年净利6.33亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072758","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072758?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:55","pubTimestamp":1769882111,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，诺诚健华报收于21.4元，较上周的20.29元上涨5.47%。本周，诺诚健华1月30日盘中最高价报22.5元。诺诚健华当前最新总市值377.63亿元，在化学制药板块市值排名12/150，在两市A股市值排名553/5184。业绩披露要点诺诚健华发布业绩预告，预计2025年全年归属净利润盈利约6.33亿元。公司公告汇总诺诚健华医药有限公司预计2025年实现营业总收入约23.65亿元，同比增长134%左右。扣除非经常性损益后的净利润为5.34亿元左右，同比增加9.74亿元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428","BK0239","BK1574","BK1161"],"gpt_icon":0},{"id":"2607628066","title":"诺诚健华(09969.HK)高开逾13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607628066","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607628066?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:36","pubTimestamp":1769736987,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺诚健华(09969.HK)高开逾13%，截至发稿，涨13.6%，报13.2港元，成交额1099.56万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303636358961.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636358961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","09969","BK1574","BK1161","688428"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.0446},{"period":"1month","weight":-0.0394},{"period":"3month","weight":-0.1451},{"period":"6month","weight":-0.3381},{"period":"1year","weight":0.9006},{"period":"ytd","weight":0.0106}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0052},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.0612},{"period":"1year","weight":0.1806},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.133758},{"month":3,"riseRate":0,"avgChangeRate":-0.036551},{"month":4,"riseRate":0.666667,"avgChangeRate":0.116223},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.042592},{"month":6,"riseRate":0.833333,"avgChangeRate":0.12939},{"month":7,"riseRate":0.5,"avgChangeRate":0.039258},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}